ResearcherCharité – Universitätsmedizin BerlinNo recent work listed
S Daum
Matched on ORCID iD 0000-0003-0060-6013; OpenAlex author ID A5019301410. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 25
2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper
Papers 3
- Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic canc… Co-author DOI 10.1016/j.annonc.2022.09.161↗
- [Long-term response in advanced pancreatic adenocarcinoma - a case report and literature review]. Last author DOI 10.1055/a-1695-3528↗
- Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, r… Co-author DOI 10.1186/s12885-018-5183-y↗
Closest collaborators
The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Paola Cura Daball · 1 shared paper, 2022 · strength 0.26
- Eike Gallmeier · 2 shared papers, 2018–2023 · strength 0.18
- Paper Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized p… DOI 10.1016/j.annonc.2022.09.161↗
- Paper Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONA… DOI 10.1186/s12885-018-5183-y↗
- Andrea Tannapfel · 2 shared papers, 2018–2023 · strength 0.18
- Paper Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized p… DOI 10.1016/j.annonc.2022.09.161↗
- Paper Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONA… DOI 10.1186/s12885-018-5183-y↗
- Thomas Jens Ettrich · 2 shared papers, 2018–2023 · strength 0.18
- Paper Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized p… DOI 10.1016/j.annonc.2022.09.161↗
- Paper Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONA… DOI 10.1186/s12885-018-5183-y↗
- Waldemar H. Uhl · 2 shared papers, 2018–2023 · strength 0.18
- Paper Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized p… DOI 10.1016/j.annonc.2022.09.161↗
- Paper Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONA… DOI 10.1186/s12885-018-5183-y↗
- Michael Geißler · 2 shared papers, 2018–2023 · strength 0.18
- Paper Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized p… DOI 10.1016/j.annonc.2022.09.161↗
- Paper Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONA… DOI 10.1186/s12885-018-5183-y↗
- Thomas Theodor Werner Seufferlein · 2 shared papers, 2018–2023 · strength 0.18
- Paper Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized p… DOI 10.1016/j.annonc.2022.09.161↗
- Paper Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONA… DOI 10.1186/s12885-018-5183-y↗
- Anke Reinacher‐Schick · 2 shared papers, 2018–2023 · strength 0.18
- Paper Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized p… DOI 10.1016/j.annonc.2022.09.161↗
- Paper Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONA… DOI 10.1186/s12885-018-5183-y↗
- Alexander Otto König · 2 shared papers, 2018–2023 · strength 0.18
- Paper Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized p… DOI 10.1016/j.annonc.2022.09.161↗
- Paper Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONA… DOI 10.1186/s12885-018-5183-y↗
- Uwe A. Wittel · 2 shared papers, 2018–2023 · strength 0.18
- Paper Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized p… DOI 10.1016/j.annonc.2022.09.161↗
- Paper Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONA… DOI 10.1186/s12885-018-5183-y↗
- Hana Algül · 2 shared papers, 2018–2023 · strength 0.18
- Paper Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized p… DOI 10.1016/j.annonc.2022.09.161↗
- Paper Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONA… DOI 10.1186/s12885-018-5183-y↗
- Marko Kornmann · 2 shared papers, 2018–2023 · strength 0.18
- Paper Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized p… DOI 10.1016/j.annonc.2022.09.161↗
- Paper Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONA… DOI 10.1186/s12885-018-5183-y↗
- Lukas Perkhofer · 2 shared papers, 2018–2023 · strength 0.18
- Paper Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized p… DOI 10.1016/j.annonc.2022.09.161↗
- Paper Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONA… DOI 10.1186/s12885-018-5183-y↗
- Jasmin Schuhbaur · 1 shared paper, 2023 · strength 0.12
- Michael B. Ghadimi · 1 shared paper, 2023 · strength 0.12
- Volker Kunzmann · 1 shared paper, 2023 · strength 0.12
- Ingo Klein · 1 shared paper, 2023 · strength 0.12
- Detlef Klaus Bartsch · 1 shared paper, 2023 · strength 0.12
- Manfred Paul Lutz · 1 shared paper, 2023 · strength 0.12
- Alexander Kleger · 1 shared paper, 2023 · strength 0.12
- Helmut Friess · 1 shared paper, 2023 · strength 0.12
- Angelika M. R. Kestler · 1 shared paper, 2023 · strength 0.12
- Margaret A. Tempero · 1 shared paper, 2023 · strength 0.12
- Christiane J. Bruns · 1 shared paper, 2023 · strength 0.12
- Andreas Wolfgang Berger · 1 shared paper, 2018 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.